ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ranbaxy Laboratories and GlaxoSmithKline have signed an R&D agreement that expands the terms of one signed in 2003.
Under the original deal, Ranbaxy limited itself to optimization chemistry work on drug leads. Now, the Delhi-based firm will continue developing leads to the point of clinical proof of concept.
The new agreement also clarifies the conditions under which GSK will make milestone and royalty payments. Ranbaxy says it could receive more than $100 million in milestone payments as well as royalties in the double-digit range on sales of commercial products.
The firms say they will collaborate to develop anti-infective, metabolic, respiratory, and oncology products. GSK is managing the collaboration as part of its Center of Excellence for External Drug Discovery (CEEDD), which is an attempt to boost the company's pipeline by relying on the research capabilities of third parties.
"This expanded agreement builds on the success of the existing collaboration and furthers our CEEDD strategy of building a strong pipeline through to clinical proof of concept via external R&D collaborations," says Maxine Gowen, senior vice president of the CEEDD.
Ranbaxy employs a total of 1,200 scientists, 300 of whom are engaged in drug discovery work. "I believe the arrangement with GSK is path-breaking and acknowledges the higher level of R&D maturity prevalent today in our state-of-the-art labs in India," says Ranbaxy CEO Malvinder M. Singh.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter